02/10/2021 Sanifit Granted Orphan Drug Designation by the FDA for SNF472 for the Treatment of Peripheral Arterial Disease in Patients with End-stage Kidney Disease
11/10/2020 Subgroup Analyses from Sanifit’s CaLIPSO Phase 2b Clinical Study Published in Kidney International Reports
10/22/2020 Sanifit Presents New Data for SNF472 in Treatment of Vascular Calcification at ASN Kidney Week 2020
10/12/2020 Sanifit to Present New Data on SNF472 for Vascular Calcification at the American Society of Nephrology Kidney Week 2020
08/06/2020 Biotech innovation in Spain: the European Investment Bank provides €20 million in financing to Sanifit to develop treatments for vascular calcification
07/20/2020 Sanifit to start new clinical development program of SNF472 in End Stage Kidney Disease patients with Peripheral Artery Disease
